{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:21:48Z","timestamp":1790238108355,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01MH093529"],"award-info":[{"award-number":["R01MH093529"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.schres.2017.01.008","type":"journal-article","created":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T20:45:37Z","timestamp":1484340337000},"page":"88-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["A 12-week randomized controlled trial of twice-daily intranasal oxytocin for social cognitive deficits in people with schizophrenia"],"prefix":"10.1016","volume":"185","author":[{"given":"L. Fredrik","family":"Jarskog","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cort A.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline L.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Hamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane W.","family":"Rau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonya","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Penn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6684","key":"10.1016\/j.schres.2017.01.008_bb0005","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/30982","article-title":"The human amygdala in social judgment","volume":"393","author":"Adolphs","year":"1998","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.schres.2017.01.008_bb0010","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1210\/jcem-57-5-947","article-title":"A time-dependent peak of oxytocin exists in cerebrospinal fluid but not in plasma of humans","volume":"57","author":"Amico","year":"1983","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.schres.2017.01.008_bb0015","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1017\/S0033291711001413","article-title":"Emotion recognition and oxytocin in patients with schizophrenia","volume":"42","author":"Averbeck","year":"2012","journal-title":"Psychol. Med."},{"issue":"3","key":"10.1016\/j.schres.2017.01.008_bb0020","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.biopsych.2012.08.025","article-title":"Chronic intranasal oxytocin causes long-term impairments in partner preference formation in male prairie voles","volume":"74","author":"Bales","year":"2013","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2017.01.008_bb0025","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/1469-7610.00715","article-title":"The \u201creading the mind in the eyes\u201d test revised version: a study with normal adults, and adults with Asperger syndrome or high-functioning autism","volume":"42","author":"Baron-Cohen","year":"2001","journal-title":"J. Child Psychol. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2017.01.008_bb0030","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.schres.2015.06.007","article-title":"Effects of oxytocin and genetic variants on brain and behaviour: implications for treatment in schizophrenia","volume":"168","author":"Bartholomeusz","year":"2015","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.schres.2017.01.008_bb0035","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.neuron.2008.04.009","article-title":"Oxytocin shapes the neural circuitry of trust and trust adaptation in humans","volume":"58","author":"Baumgartner","year":"2008","journal-title":"Neuron"},{"issue":"1\u20133","key":"10.1016\/j.schres.2017.01.008_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2008.12.020","article-title":"Theory of mind impairment in schizophrenia: meta-analysis","volume":"109","author":"Bora","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2017.01.008_bb0045","series-title":"The social brain: evolution and pathology","first-page":"277","article-title":"Social Cognition and Behaviour in Schizophrenia","author":"Br\u00fcne","year":"2003"},{"issue":"2","key":"10.1016\/j.schres.2017.01.008_bb0050","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/schbul\/sbu094","article-title":"A double-blind randomized controlled trial of oxytocin nasal spray and social cognition training for young people with early psychosis","volume":"41","author":"Cacciotti-Saija","year":"2015","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.schres.2017.01.008_bb0055","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1080\/13546800600787854","article-title":"The Ambiguous Intentions Hostility Questionnaire (AIHQ): a new measure for evaluating hostile social-cognitive biases in paranoia","volume":"12","author":"Combs","year":"2007","journal-title":"Cogn. Neuropsychiatry"},{"issue":"2\u20133","key":"10.1016\/j.schres.2017.01.008_bb0060","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.schres.2013.04.023","article-title":"Effects of single dose intranasal oxytocin on social cognition in schizophrenia","volume":"147","author":"Davis","year":"2013","journal-title":"Schizophr. Res."},{"issue":"9","key":"10.1016\/j.schres.2017.01.008_bb0065","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1038\/npp.2014.68","article-title":"Oxytocin-augmented social cognitive skills training in schizophrenia","volume":"39","author":"Davis","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"10.1016\/j.schres.2017.01.008_bb0070","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.biopsych.2007.03.025","article-title":"Oxytocin attenuates amygdala responses to emotional faces regardless of valence","volume":"62","author":"Domes","year":"2007","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2017.01.008_bb0075","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.biopsych.2015.07.025","article-title":"A review of Oxytocin's effects on the positive, negative, and cognitive domains of schizophrenia","volume":"79","author":"Feifel","year":"2016","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2017.01.008_bb0080","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.neubiorev.2010.07.001","article-title":"The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis","volume":"35","author":"Fett","year":"2011","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"2\u20133","key":"10.1016\/j.schres.2017.01.008_bb0085","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.schres.2014.04.009","article-title":"A pilot six-week randomized controlled trial of oxytocin on social cognition and social skills in schizophrenia","volume":"156","author":"Gibson","year":"2014","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2017.01.008_bb0090","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00213-011-2193-8","article-title":"Divergent effects of two different doses of intranasal oxytocin on facial affect discrimination in schizophrenic patients with and without polydipsia","volume":"216","author":"Goldman","year":"2011","journal-title":"Psychopharmacology"},{"issue":"7","key":"10.1016\/j.schres.2017.01.008_bb0095","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.biopsych.2009.09.020","article-title":"Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders","volume":"67","author":"Guastella","year":"2010","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2017.01.008_bb0100","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.schres.2015.06.005","article-title":"A single dose of oxytocin nasal spray improves higher-order social cognition in schizophrenia","volume":"168","author":"Guastella","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2017.01.008_bb0105","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0079-6123(08)00428-7","article-title":"Neuropeptides and social behaviour: effects of oxytocin and vasopressin in humans","volume":"170","author":"Heinrichs","year":"2008","journal-title":"Prog. Brain Res."},{"issue":"4","key":"10.1016\/j.schres.2017.01.008_bb0110","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.biopsych.2006.05.030","article-title":"Oxytocin increases retention of social cognition in autism","volume":"61","author":"Hollander","year":"2007","journal-title":"Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2017.01.008_bb0115","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/npp.2013.310","article-title":"Chronic and acute intranasal oxytocin produce divergent social effects in mice","volume":"39","author":"Huang","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.schres.2017.01.008_bb0120","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"Suppl. 2","key":"10.1016\/j.schres.2017.01.008_bb0125","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1093\/schbul\/sbt158","article-title":"Progress in the study of negative symptoms","volume":"40","author":"Kirkpatrick","year":"2014","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.schres.2017.01.008_bb0130","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1017\/S1092852900009202","article-title":"Recognition of facial emotions in neuropsychiatric disorders","volume":"9","author":"Kohler","year":"2004","journal-title":"CNS Spectr."},{"issue":"5","key":"10.1016\/j.schres.2017.01.008_bb0135","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/schbul\/sbn192","article-title":"Facial emotion perception in schizophrenia: a meta-analytic review","volume":"36","author":"Kohler","year":"2010","journal-title":"Schizophr. Bull."},{"issue":"7042","key":"10.1016\/j.schres.2017.01.008_bb0140","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nature03701","article-title":"Oxytocin increases trust in humans","volume":"435","author":"Kosfeld","year":"2005","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.schres.2017.01.008_bb0145","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3109\/08039488.2012.700731","article-title":"Associations between the oxytocin receptor gene (OXTR) and \u201cmind-reading\u201d in humans\u2013an exploratory study","volume":"67","author":"Lucht","year":"2013","journal-title":"Nord. J. Psychiatry"},{"key":"10.1016\/j.schres.2017.01.008_bb0150","first-page":"194","article-title":"Sex, receptors, and attachment: a review of individual factors influencing response to oxytocin","volume":"6","author":"Macdonald","year":"2012","journal-title":"Front. Neurosci."},{"issue":"4","key":"10.1016\/j.schres.2017.01.008_bb0155","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00213-012-2775-0","article-title":"The influence of oxytocin administration on responses to infant faces and potential moderation by OXTR genotype","volume":"224","author":"Marsh","year":"2012","journal-title":"Psychopharmacology (Berlin)"},{"issue":"9","key":"10.1016\/j.schres.2017.01.008_bb0160","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nrn3044","article-title":"Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine","volume":"12","author":"Meyer-Lindenberg","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"issue":"1","key":"10.1016\/j.schres.2017.01.008_bb0165","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.biopsych.2008.04.024","article-title":"The social-emotional processing stream: five core constructs and their translational potential for schizophrenia and beyond","volume":"64","author":"Ochsner","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2017.01.008_bb0170","article-title":"Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials","author":"Oya","year":"2015","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"2\u20133","key":"10.1016\/j.schres.2017.01.008_bb0175","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0920-9964(00)00109-2","article-title":"Social skills performance assessment among older patients with schizophrenia","volume":"48","author":"Patterson","year":"2001","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2017.01.008_bb0180","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.schres.2011.07.027","article-title":"Intranasal oxytocin reduces psychotic symptoms and improves theory of mind and social perception in schizophrenia","volume":"132","author":"Pedersen","year":"2011","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2017.01.008_bb0185","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.schres.2009.08.016","article-title":"The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial","volume":"115","author":"Penn","year":"2009","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.schres.2017.01.008_bb0190","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/schbul\/sbt081","article-title":"The social cognition psychometric evaluation study: results of the expert survey and RAND panel","volume":"40","author":"Pinkham","year":"2014","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.schres.2017.01.008_bb0195","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/schbul\/sbv056","article-title":"Social cognition psychometric evaluation: results of the initial psychometric study","volume":"42","author":"Pinkham","year":"2016","journal-title":"Schizophr. Bull."},{"issue":"1\u20133","key":"10.1016\/j.schres.2017.01.008_bb0200","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.schres.2011.06.002","article-title":"Sex-specific associations between peripheral oxytocin and emotion perception in schizophrenia","volume":"130","author":"Rubin","year":"2011","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.schres.2017.01.008_bb0205","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/swra\/19.3.9","article-title":"SLOF: a behavioral rating scale for assessing the mentally ill","volume":"19","author":"Schneider","year":"1983","journal-title":"Soc. Work Res. Abstr."},{"issue":"9","key":"10.1016\/j.schres.2017.01.008_bb0210","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.psyneuen.2011.03.011","article-title":"Oxytocin increases recognition of masked emotional faces","volume":"36","author":"Schulze","year":"2011","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.schres.2017.01.008_bb0215","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.psyneuen.2014.04.024","article-title":"Oxytocin administration enhances controlled social cognition in patients with schizophrenia","volume":"47","author":"Woolley","year":"2014","journal-title":"Psychoneuroendocrinology"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996417300075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996417300075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T04:03:12Z","timestamp":1656820992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996417300075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":43,"alternative-id":["S0920996417300075"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2017.01.008","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A 12-week randomized controlled trial of twice-daily intranasal oxytocin for social cognitive deficits in people with schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2017.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}